Stem Cells: Cell-Based Assays and the World of Small Molecules By Dr Christina N. Ramirez, Dr Dana C. Duré and Dr Hakim Djaballah Stem cells remain a hot topic in academia and industry alike, and with the potential to cause a paradigm shift where many believe in their… Read More
Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in… Read More
In Vivo Imaging In Drug Development: Gamma Scintigraphy By Dr Alyson Connor Gamma scintigraphy is a non-invasive technique with applications in the development of drug products and the assessment of pharmacodynamic effects in humans. It enables the assessment of critical performance parameters that in vitro techniques attempt,… Read More
By Dr Jeffrey Dage and Dr Kalpana Merchant While the jury is still out in terms of iPS cell technology and its ability to deliver a regenerative therapy or, indeed, contribute to the development of a clinical molecule, this paper argues that the progress by… Read More
The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation. By Chris Molloy A leading ballet conductor (1) recently told me of courses which he runs for senior business leaders. He allows them to conduct an orchestra: first, very strictly, with close… Read More
Pathway Analysis – Understanding the bridge between environmental cues and cellular response By Dr John Comley Understanding the function of a protein in the context of normal and abnormal cellular processes requires a comprehensive knowledge not only of its regulation but also of its role in signalling and… Read More
Biological Analysis and Interpretation For Improved Research Outcomes By Dr Douglas Bassett In the last few years, technological advancements in the life sciences have changed many ways in which we think about research. Next-generation sequencing, qPCR and microRNA offer new avenues to ask and answer research questions in… Read More
Current and Emerging Trends In Immunogenicity Research In November 2011 Drug Discovery World hosted a collegial style roundtable discussion on the present and emerging developments in this fundamental area of drug discovery and development. The participants are drawn from the biopharmaceutical, biotechnology and vendor community. Although somewhat… Read More
Optimising Well Results In Label-Free Analysis By Dr Stephan Heyse, Dr Oliver Leven and Dr Jon Tupy Bearing in mind the cost and time required to conduct a screening campaign, it is of paramount importance that screening laboratory scientists process and analyse screen data as carefully and consistently… Read More
From Outsourced To Open: The continuing evolution of the drug discovery business model Dr Mary Canady One doesn’t have to look far to find that the large pharmaceutical business model has many market forces working against it, such as patent expirations, dwindling pipelines, and reduced R&D productivity. However,… Read More
Ontario as a Life Sciences Powerhouse By Michael Stewart Around the world, competition between life sciences companies is fierce. And so is the competition between jurisdictions wanting to attract the good paying jobs, innovative spirit and R&D that comes along with this important economic sector. Read More
Share Share Tweet Email Stem Cell Banks: Investing in the promise of cancer stem cell science Stem Cell Banks: Investing in the promise of cancer stem cell science By Madeline Page and Rosario Isasi The… Read More
Simultaneous Visualisation of Attrition and Timelines: Funnel Diagrams. By Dr Linda Hirons, Dr Craig Johnstone and Colin Sambrook-Smith In drug discovery both attrition and timelines are important factors to consider when applying process improvement to lead optimisation. In our attempts to improve the visualisation of both of these… Read More
Small Scale Benchtop Automation: Broadening the adoption of lab automation By Dr John Comley Driven by the need to enable technically challenging or repetitive processes, many labs in drug discovery that were not previously adopters of laboratory automation are being increasingly drawn to the potential of simple… Read More
When High Content Screening Meets High Throughput By Dr Vincent Unterreiner and Dr Daniela Gabriel The terms High Content Imaging (HCI) and High Throughput Screening (HTS) were introduced more than a decade ago (1) and are defining the use of automated microscopy and automated image analysis in the… Read More
The Apocalyptic Horsemen of Drug Discovery and Development By Dr Gary J. Keil The pharmaceutical industry should consider an evolutionary disease management approach based on homeostasis, irreversibility, biological alinearity, pseudo-N-of-1 health and disease states and narrative medicine best practices in order to help secure a successful drug… Read More
